Crefmirlimab - ImaginAb Inc
Alternative Names: 89-Zr CD8 ImmunoPET minibody - ImaginAb Inc; 89Zr CD8 Immuno-PET agent - ImaginAb; 89Zr-crefmirlimab berdoxam - ImaginAb; 89Zr-Df-crefmirlimab - ImaginAb; 89Zr-Df-IAB22M2C - ImaginAb; [89Zr]-Df-Crefmirlimab; [89Zr]Df-IAB22M2C; CD8 T cell I/O imaging agent; CD8 T Cell imaging agent; CD8-ImmunoPET; IAB 22 M2C; Minibody CD8 T Cell imaging agent; Zirconium 89Zr crefmirlimab berdoxam; Zr-89 IAB22M2CLatest Information Update: 07 Aug 2024
At a glance
- Originator ImaginAb Inc
- Class Antibody diagnostics; Antineoplastics; Diagnostic agents; Imaging agents; Immunoconjugates; Immunoglobulin fragments; Radioisotopes; Radiopharmaceutical diagnostics; Radiopharmaceuticals
- Mechanism of Action Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Malignant melanoma; Renal cell carcinoma
- Phase II Inclusion body myositis; Merkel cell carcinoma; Non-small cell lung cancer; Solid tumours
- No development reported Cervical cancer; Gastric cancer; Graft-versus-host disease
Most Recent Events
- 02 Aug 2024 ImaginAB in collaboration with University Medical Center Groningen plans a phase II trial for Solid tumours (Late-stage disease, Metastatic disease, Second line therapy or greater, Diagnosis) in Netherlands, Spain and United Kingdom (Unspecified)(NCT06534190)
- 25 Jan 2024 Interim pharmacokinetics data from a phase II in solid tumours presented at the 2024 Genitourinary Cancers Symposium (ASCO-GSC-2024)
- 02 Jun 2023 Efficacy data from phase II trial for Solid tumours presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)